127 related articles for article (PubMed ID: 37652303)
1. Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer.
Yegya-Raman N; Berman AT; Ciunci CA; Friedes C; Berlin E; Iocolano M; Wang X; Lai C; Levin WP; Cengel KA; O'Reilly SE; Cohen RB; Aggarwal C; Marmarelis ME; Singh AP; Sun L; Bradley JD; Plastaras JP; Simone CB; Langer CJ; Feigenberg SJ
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):56-65. PubMed ID: 37652303
[TBL] [Abstract][Full Text] [Related]
2. Reirradiation With Proton Therapy for Recurrent Malignancies of the Esophagus and Gastroesophageal Junction: Results of the Proton Collaborative Group Multi-Institutional Prospective Registry Trial.
Hotca A; Sindhu KK; Lehrer EJ; Hartsell WF; Vargas C; Tsai HK; Chang JH; Apisarnthanarax S; Nichols RC; Chhabra AM; Hasan S; Press RH; Lazarev S; Hajj C; Kabarriti R; Rule WG; Simone CB; Choi JI
Adv Radiat Oncol; 2024 May; 9(5):101459. PubMed ID: 38596455
[TBL] [Abstract][Full Text] [Related]
3. Proton reirradiation for recurrent or new primary breast cancer in the setting of prior breast irradiation.
Choi JI; Khan AJ; Powell SN; McCormick B; Lozano AJ; Del Rosario G; Mamary J; Liu H; Fox P; Gillespie E; Braunstein LZ; Mah D; Cahlon O
Radiother Oncol; 2021 Dec; 165():142-151. PubMed ID: 34688807
[TBL] [Abstract][Full Text] [Related]
4. Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation.
Verma V; Rwigema JM; Malyapa RS; Regine WF; Simone CB
Radiother Oncol; 2017 Oct; 125(1):21-30. PubMed ID: 28941560
[TBL] [Abstract][Full Text] [Related]
5. Proton beam therapy reirradiation for breast cancer: Multi-institutional prospective PCG registry analysis.
Thorpe CS; Niska JR; Girardo ME; Kosiorek HE; McGee LA; Hartsell WF; Larson GL; Tsai HK; Rossi CJ; Rosen LR; Vargas CE
Breast J; 2019 Nov; 25(6):1160-1170. PubMed ID: 31338974
[TBL] [Abstract][Full Text] [Related]
6. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.
Durm GA; Jabbour SK; Althouse SK; Liu Z; Sadiq AA; Zon RT; Jalal SI; Kloecker GH; Williamson MJ; Reckamp KL; Langdon RM; Kio EA; Gentzler RD; Adesunloye BA; Harb WA; Walling RV; Titzer ML; Hanna NH
Cancer; 2020 Oct; 126(19):4353-4361. PubMed ID: 32697352
[TBL] [Abstract][Full Text] [Related]
8. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD
JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865
[TBL] [Abstract][Full Text] [Related]
9. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes.
McAvoy S; Ciura K; Wei C; Rineer J; Liao Z; Chang JY; Palmer MB; Cox JD; Komaki R; Gomez DR
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):819-27. PubMed ID: 25220718
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Study of Proton Beam Reirradiation for Esophageal Cancer.
Fernandes A; Berman AT; Mick R; Both S; Lelionis K; Lukens JN; Ben-Josef E; Metz JM; Plastaras JP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):483-487. PubMed ID: 26847847
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma.
Lee A; Woods R; Mahfouz A; Kitpanit S; Cartano O; Mohamed N; Youssef I; Marqueen K; Sine K; Mah D; Neal B; Zakeri K; Kang JJ; Riaz N; Yu Y; McBride SM; Chen LD; Tsai CJ; Gelblum DY; Press RH; Michel LS; Sherman EJ; Pfister D; Dunn LA; Ho AL; Fetten J; Wong RJ; Boyle JO; Singh B; Cracchiolo JR; Ganly I; Cohen MA; Lee NY
JAMA Netw Open; 2023 Jan; 6(1):e2250607. PubMed ID: 36689229
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies.
Badiyan SN; Rutenberg MS; Hoppe BS; Mohindra P; Larson G; Hartsell WF; Tsai H; Zeng J; Rengan R; Glass E; Katz S; Vargas C; Feigenberg SJ; Simone CB
Pract Radiat Oncol; 2019; 9(4):280-288. PubMed ID: 30802618
[TBL] [Abstract][Full Text] [Related]
13. Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinoma.
Kruser TJ; McCabe BP; Mehta MP; Khuntia D; Campbell TC; Geye HM; Cannon GM
Am J Clin Oncol; 2014 Feb; 37(1):70-6. PubMed ID: 23357968
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer.
McAvoy SA; Ciura KT; Rineer JM; Allen PK; Liao Z; Chang JY; Palmer MB; Cox JD; Komaki R; Gomez DR
Radiother Oncol; 2013 Oct; 109(1):38-44. PubMed ID: 24016675
[TBL] [Abstract][Full Text] [Related]
15. Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer.
Chao HH; Berman AT; Simone CB; Ciunci C; Gabriel P; Lin H; Both S; Langer C; Lelionis K; Rengan R; Hahn SM; Prabhu K; Fagundes M; Hartsell W; Mick R; Plastaras JP
J Thorac Oncol; 2017 Feb; 12(2):281-292. PubMed ID: 27826034
[TBL] [Abstract][Full Text] [Related]
16. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
[TBL] [Abstract][Full Text] [Related]
17. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer.
Welsh JW; Heymach JV; Chen D; Verma V; Cushman TR; Hess KR; Shroff G; Tang C; Skoulidis F; Jeter M; Menon H; Nguyen QN; Chang JY; Altan M; Papadimitrakopoulou VA; Simon GR; Raju U; Byers L; Glisson B
J Thorac Oncol; 2020 Feb; 15(2):266-273. PubMed ID: 31605794
[TBL] [Abstract][Full Text] [Related]
18. Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity.
Marwah R; Xing D; Squire T; Soon YY; Gan HK; Ng SP
J Neurooncol; 2023 Sep; 164(3):505-524. PubMed ID: 37733174
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.
Anouti B; Althouse S; Durm G; Hanna N
Clin Lung Cancer; 2020 May; 21(3):288-293. PubMed ID: 32143966
[TBL] [Abstract][Full Text] [Related]
20. Reirradiation for locoregionally recurrent non-small cell lung cancer.
Vyfhuis MAL; Rice S; Remick J; Mossahebi S; Badiyan S; Mohindra P; Simone CB
J Thorac Dis; 2018 Aug; 10(Suppl 21):S2522-S2536. PubMed ID: 30206496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
